Phibro Animal Health Corporation Class A (PAHC)
Nasdaq Market Closed
Phibro Animal Health Corporation is a diversified animal health and nutrition company serving livestock producers, veterinarians, feed manufacturers, and agricultural distributors. Its products are used in the care and productivity of food animals, including poultry, swine, beef cattle, dairy cattle, and aquaculture species, giving the company exposure to global protein production and food supply chains.
The company operates through three main segments: Animal Health, Mineral Nutrition, and Performance Products. Animal Health is the core business and includes antibacterials, anticoccidials, vaccines, and nutritional specialty products designed to support animal well-being, disease prevention, feed efficiency, and overall herd or flock performance. These products are used in commercial farming systems where animal health, consistency, and productivity are central to profitability.
Phibro’s Mineral Nutrition segment supplies trace minerals and related ingredients that are incorporated into animal feed. These inputs help address nutritional requirements that vary by species, stage of growth, and production system. The Performance Products segment includes specialty ingredients and industrial products that broaden the company’s revenue base beyond its principal animal health franchise.
The company sells in the United States and international markets, reflecting the global nature of livestock and aquaculture production. Demand for its portfolio is shaped by meat, milk, egg, and fish consumption, disease pressures, farm economics, feed costs, and regulatory rules governing animal health products. Phibro’s distinctive position lies in combining pharmaceuticals, vaccines, feed additives, and nutritional technologies for production animals, rather than focusing solely on companion animal care or human healthcare.
Last updated
- Market Cap
- 1.16B
- P/E
- 12.15
- P/FCF
- 90.59
- P/S
- 0.77
- Enterprise Value
- 1.84B
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ, 07666
Glycolic Acid Market is expected to generate a revenue of USD 461.74 Million by 2032, Globally, at 5.73% CAGR: Verified Market Research®
Poultry Vaccine & Drug Market Booming as Demand for Disease Prevention Increases
Growth Trends in the Porcine Vaccines Market, Forecast to 2028: Increasing Government Initiatives for Funding Animal Husbandry
UAE Veterinary Medicine Market, By Region, Competition, Forecast and Opportunities, 2029F
Animal Feed Minerals Market Set to Grow at 3.9% CAGR from 2024 to 2034, Reaching USD 6.1 Billion | Future Market Insights, Inc.
Poultry Vaccines Market Size and Forecast, Global and Regional Share, Trends, and Growth Opportunity Analysis Report 2024
Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?
Global Swine Healthcare Market Size To Worth USD 5.96 Billion By 2033 | CAGR of 8.16% - GlobeNewswire
Zacks Value Trader Highlights: Great Lakes Dredge & Dock, HanesBrands, Lands' End, Phibro Animal Health and Wolverine World Wide - Zacks Investment Research
How to Invest in Small Cap Value Stocks in 2024 - Zacks Investment Research
Beat the Market Like Zacks: Freshpet, AudioEye, Walmart in Focus
Phibro (PAHC) Upgraded to Strong Buy: What Does It Mean for the Stock?
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
Phibro (PAHC) Down 3.3% Since Last Earnings Report: Can It Rebound?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Haemonetics Corporation (HAE) Hit a 52 Week High, Can the Run Continue?
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Interpreting Phibro (PAHC) International Revenue Trends
Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down
Phibro (PAHC) Reports Q3 Earnings: What Key Metrics Have to Say
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 1.16B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 1.84B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 12.15
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.2
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.77
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 7.97
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.22
- EPS
- 2.35
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 1.68%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 90.59
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 17.49
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 12.77M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 26.32%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 6.59%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 2.03
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.17
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.26
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.19
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 421.42K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 28.52
Income Statement
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Revenue | 383.54M | 373.91M | 363.89M | 378.7M | 347.83M |
| Gross profit | 125.68M | 132.66M | 119.78M | 110.01M | 104.57M |
| Operating income | 44.65M | 50.33M | 51.26M | 33.72M | 33.52M |
| EBITDA | 57.1M | 63.22M | 64.09M | 46.13M | 46.13M |
| Net income | 24.02M | 27.46M | 26.53M | 17.22M | 20.88M |
| Basic EPS | 0.59 | 0.68 | 0.65 | 0.42 | 0.52 |
| Diluted EPS | 0.59 | 0.67 | 0.65 | 0.43 | 0.51 |
Balance Sheet
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total assets | 1.45B | 1.41B | 1.39B | 1.36B | 1.32B |
| Total liabilities | 1.08B | 1.07B | 1.07B | 1.08B | 1.05B |
| Total equity | 361.83M | 332.36M | 311.68M | 285.68M | 265.99M |
| Cash & equivalents | 54.93M | 55.49M | 72.77M | 68.04M | 60.35M |
| Current assets | 894.07M | 862.19M | 835.8M | 810.61M | 776.02M |
| Current liabilities | 281.87M | 282.37M | 270.14M | 293.47M | 266.48M |
Cash Flow
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating cash flow | 16.21M | 19.35M | 9.3M | 21.27M | 43.15M |
| Investing cash flow | -16.81M | -17.18M | -21.01M | -7.03M | -18.25M |
| Financing cash flow | -2.3M | -18.98M | 16.34M | -7.77M | -32.22M |
| Change in cash | -557K | -17.28M | 4.73M | 7.69M | -6.72M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13D/A — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| edgar index | 4 — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| edgar index | 10-Q — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| edgar index | 8-K — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| edgar index | 8-K — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| edgar index | 8-K — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| edgar index | SCHEDULE 13D/A — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| edgar index | 4 — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| edgar index | 8-K — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| edgar index | SCHEDULE 13G — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| edgar index | 4 — PHIBRO ANIMAL HEALTH CORP | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BFI Co., LLC | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing | |
| form 4 | Form 4 — BENDHEIM JACK | View Filing |